Molecular Analysis of the HIV-1 Resistance Development: Enzymatic Activities, Crystal Structures, and Thermodynamics of Nelfinavir-resistant HIV Protease Mutants

Journal of Molecular Biology

Volumn 374, Issue 4, 2007, Pages 1005-1016

  Kožíšek, Milan ^a,b   Bray, Jenelle ^c   Řezáčová, Pavlína ^d   Šašková, Klára ^a,b   Brynda, Jiří ^a,d   Pokorná, Jana ^a   Mammano, Fabrizio ^e   Rulíšek, Lubomír ^a   Konvalinka, Jan ^a,b  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^d INSTITUTE OF MATHEMATICS   (Czech Republic)

^e BICHAT HOSPITAL   (France)

Author keywords

antiviral resistance development; HIV protease inhibitors; isothermal calorimetry; protease inhibitor structure

Indexed keywords

NELFINAVIR; PROTEINASE; RECOMBINANT ENZYME;

ARTICLE; CRYSTAL STRUCTURE; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITOR INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; THERMODYNAMICS; VIRUS MUTANT; VIRUS MUTATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 35748950982     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.09.083     Document Type: Article

References (48)

1. Turner B.G., and Summers M.F. Structural biology of HIV. J. Mol. Biol. 285 (1999) 1-32
2. Kohl N.E., Emini E.A., Schleif W.A., Davis L.J., Heimbach J.C., Dixon R.A., et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl Acad. Sci. USA 85 (1988) 4686-4690
3. Condra J.H., Schleif W.A., Blahy O.M., Gabryelski L.J., Graham D.J., Quintero J.C., et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374 (1995) 569-571
4. Surleraux D.L., de Kock H.A., Verschueren W.G., Pille G.M., Maes L.J., Peeters A., et al. Design of HIV-1 protease inhibitors active on multidrug-resistant virus. J. Med. Chem. 48 (2005) 1965-1973
5. Bardsley-Elliot A., and Plosker G.L. Nelfinavir: an update on its use in HIV infection. Drugs 59 (2000) 581-620
6. Patick A.K., Duran M., Cao Y., Shugarts D., Keller M.R., Mazabel E., et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42 (1998) 2637-2644
7. Sugiura W., Matsuda Z., Yokomaku Y., Hertogs K., Larder B., Oishi T., et al. Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 46 (2002) 708-715
8. Oishi T., Sugiura W., Matsuda M., Abumi H., Okano A., Yamada K., et al. Status of anti-HIV-1 chemotherapy in Japan. Jpn. J. Infect. Dis. 52 (1999) 51-52
9. Perrin V., and Mammano F. Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants. J. Virol. 77 (2003) 10172-10175
10. Mitsuya Y., Winters M.A., Fessel W.J., Rhee S.-Y., Hurley L., Horberg M., et al. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. AIDS. Res. Human Retroviruses 22 (2006) 1300-1305
11. Kaldor S.W., Kalish V.J., Davies J.F., Shetty B.V., Fritz J.E., Appelt K., et al. Viracept (nelfinavir mesylate, AG1343): a potent. orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40 (1997) 3979-3985
12. Mahalingam B., Louis J.M., Reed C.C., Adomat J.M., Krouse J., Wang Y.F., et al. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur. J. Biochem. 263 (1999) 238-245
13. Clemente J.C., Moose R.E., Hemrajani R., Whitford L.R., Govindasamy L., Reutzel R., et al. Comparing the accumulation of active- and non-active-site mutations in the HIV-1 protease. Biochemistry 43 (2004) 12141-12151
14. Clemente J.C., Hemrajani R., Blum L.E., Goodenow M.M., and Dunn B.M. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N. Biochemistry 42 (2003) 15029-15035
15. Weber J., Mesters J.R., Lepsik M., Prejdova J., Svec M., Sponarova J., et al. Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains. J. Mol. Biol. 324 (2002) 739-754
16. Gulnik S.V., Suyorov L.I., Lju B., Yu B., Anderson B., Mitsuya H., and Erickson J.W. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34 (1995) 9282-9287
17. Betts M.J., and Sternberg M.J. An analysis of conformational changes on protein-protein association: implications for predictive docking. Protein Eng. 12 (1999) 271-283
18. Piana S., Carloni P., and Rothlisberger U. Drug resistance in HIV-1 protease: flexibility-assisted mechanism of compensatory mutations. Protein Sci. 11 (2002) 2393-2402
19. Mahalingam B., Louis J.M., Hung J., Harrison R.W., and Weber I.T. Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins: Struct. Funct. Genet. 43 (2001) 455-464
20. Mahalingam B., Wang Y.F., Boross P.I., Tozser J., Louis J.M., Harrison R.W., and Weber I.T. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. Eur. J. Biochem. 271 (2004) 1516-1524
21. Ode H., Ota M., Neya S., Hata M., Sugiura W., and Hoshino T. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases. J. Phys. Chem. B 109 (2005) 565-574
22. Wartha F., Horn A.H.C., Meiselbach H., and Sticht H. Molecular dynamics simulations of HIV-1 protease suggest different mechanisms contributing to drug resistance. J. Chem. Theory Comput. 1 (2005) 315-324
23. Konvalinka J., Litera J., Weber J., Vondrasek J., Hradilek M., Soucek M., et al. Configurations of diastereomeric hydroxyethylene isosteres strongly affect biological activities of a series of specific inhibitors of human-immunodeficiency-virus proteinase. Eur. J. Biochem. 250 (1997) 559-566
24. Strisovsky K., Tessmer U., Langner J., Konvalinka J., and Kraeusslich H.G. Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: rethinking the "fireman's grip" hypothesis. Protein Sci. 9 (2000) 1631-1641
25. Richards A.D., Phylip L.H., Farmerie W.G., Scarborough P.E., Alvarez A., Dunn B.M., et al. Sensitive, soluble chromogenic substrates for HIV-1 proteinase. J. Biol. Chem. 265 (1990) 7733-7736
26. Kozisek M., Prejdova J., Soucek M., Machala L., Stankova M., Linka M., et al. Characterisation of mutated proteinases derived from HIV-positive patients: enzyme activity, vitality and inhibition. Collect. Czech. Chem. Comm. 69 (2004) 703-714
27. Williams J.W., and Morrison J.F. The kinetics of reversible tight-binding inhibition. Methods Enzymol. 63 (1979) 437-467
28. Stura E.A., and Wilson I.A. Applications of the streak seeding technique in protein crystallization. J. Cryst. Growth 110 (1991) 270-282
29. Thaller C., Weaver L.H., Eichele G., Wilson E., Karlsson R., and Jansonius J.N. Repeated seeding technique for growing large single-crystals of proteins. J. Mol. Biol. 147 (1981) 465-469
30. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
31. Brynda J., Rezacova P., Fabry M., Horejsi M., Stouracova R., Soucek M., et al. Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex. Acta Crystallog. sect. D 60 (2004) 1943-1948
32. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallog. sect. D 53 (1997) 240-255
33. Bailey S. The CCP4 Suite - programs for protein crystallography. Acta Crystallog. sect. D 50 (1994) 760-763
34. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallog. sect. D 60 (2004) 2126-2132
35. Winn M.D., Murshudov M.N., and Papiz M.Z. Macromolecular TLS refinement in REFMAC at moderate resolutions. Methods Enzymol. 374 (2003) 300-321
36. Rose R.B., Craik C.S., and Stroud R.M. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. Biochemistry 37 (1998) 2607-2621
37. Ohtaka H., Velazquez-Campoy A., Xie D., and Freire E. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci. 11 (2002) 1908-1916
38. Ohtaka H., Schon A., and Freire E. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. Biochemistry 42 (2003) 13659-13666
39. Ahlrichs R., Bar M., Haser M., Horn H., and Kolmel C. Electronic structure calculations on workstation computers: the program system Turbomole. Chem. Phys. Letters 162 (1989) 165-169
40. Perdew J.P., Burke K., and Ernzerhof M. Generalized gradient approximation made simple. Phys. Rev. Letters 77 (1996) 3865-3868
41. Weigend F., and Ahlrichs R. Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: design and assessment of accuracy. Phys. Chem. Chem. Phys. 7 (2005) 3297-3305
42. Eichkorn K., Weigend F., Treutler O., and Ahlrichs R. Auxiliary basis sets for main row atoms and transition metals and their use to approximate Coulomb potentials. Theor. Chem. Acc. 97 (1997) 119-124
43. Klamt A., and Schuurmann G. Cosmo - a new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient. J. Chem. Soc. Perkin Trans. 2 (1993) 799-805
44. Klicic J.J., Friesner R.A., Liu S.Y., and Guida W.C. Accurate prediction of acidity constants in aqueous solution via density functional theory and self-consistent reaction field methods. J. Phys. Chem. ser. A 106 (2002) 1327-1335
45. Case D.A., Cheatham T.E., Darden T., Gohlke H., Luo R., Merz K.M., et al. The Amber biomolecular simulation programs. J. Comput. Chem. 26 (2005) 1668-1688
46. Berendsen H.J.C., Postma J.P.M., Vangunsteren W.F., Dinola A., and Haak J.R. Molecular-dynamics with coupling to an external bath. J. Chem. Phys. 81 (1984) 3684-3690
47. Kollman P.A., Massova I., Reyes C., Kuhn B., Huo S., Chong L., et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 33 (2000) 889-897
48. Gilson M.K., and Honig B. Calculation of the total electrostatic energy of a macromolecular system: solvation energies, binding energies, and conformational analysis. Proteins: Struct. Funct. Genet. 4 (1988) 7-18